Matching articles for "Lantus"
Issue 1743 · December 8, 2025
Insulins for Type 2 Diabetes

The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for…

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):196-9 doi:10.58347/tml.2025.1743c
The goal of pharmacologic treatment for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration while minimizing hypoglycemia; an A1C goal of <7% is recommended for most patients to prevent or reduce the microvascular complications of diabetes (retinopathy, nephropathy, neuropathy). An A1C target of <8% may be appropriate for patients who are older, have comorbid conditions, or are at risk for serious hypoglycemia-associated adverse events.
Issue 1743 · December 8, 2025 Free
Comparison Chart: Some Available Insulins for Type 2 Diabetes (online only)

View the Comparison Chart: Some Available Insulins for Type 2 Diabetes

Med Lett Drugs Ther. 2025 Dec 8; 67(1743):e201-4 doi:10.58347/tml.2025.1743d
View the Comparison Chart: Some Available Insulins for Type 2 Diabetes
Issue 1741 · November 10, 2025 Free
In Brief: Kirsty — An Insulin Aspart Interchangeable with NovoLog (online only)

The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US…

Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e185-6 doi:10.58347/tml.2025.1741g
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US that has received interchangeability status with NovoLog ; Merilog , another insulin aspart biosimilar, was approved earlier but has not received interchangeability status with NovoLog .
Issue 1731 · June 23, 2025 Free
In Brief: Merilog — A NovoLog Biosimilar

The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar…

Med Lett Drugs Ther. 2025 Jun 23; 67(1731):104 doi:10.58347/tml.2025.1731c
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Issue 1673 · April 3, 2023 Free
In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus

Insulin glargine-aglr ( Rezvoglar – Lilly), which was approved by the FDA as a biosimilar to the reference product Lantus in 2021 and received interchangeability status with Lantus in 2022, will become…

Med Lett Drugs Ther. 2023 Apr 3; 65(1673):56 doi:10.58347/tml.2023.1673c
Insulin glargine-aglr ( Rezvoglar – Lilly), which was approved by the FDA as a biosimilar to the reference product Lantus in 2021 and received interchangeability status with Lantus in 2022, will become available in the US on April 1, 2023. It is the second biosimilar insulin product to be designated as interchangeable with Lantus ; Semglee was the first. Rezvoglar did not receive interchangeability status with Lantus at the time of its initial approval because the manufacturer of Semglee had exclusivity for 12 months.
Issue 1654 · July 11, 2022
Tirzepatide (Mounjaro) for Type 2 Diabetes

The FDA has approved tirzepatide ( Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve…

Med Lett Drugs Ther. 2022 Jul 11; 64(1654):105-7
The FDA has approved tirzepatide ( Mounjaro – Lilly), a peptide hormone with activity at both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, to improve glycemic control in adults with type 2 diabetes. Tirzepatide, which is injected subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the US. Selective GIP receptor agonists are not available in the US; GLP-1 receptor agonists have been available for years.
Issue 1634 · October 4, 2021 Free
In Brief: Semglee - Insulin Glargine Interchangeable with Lantus

Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin…

Med Lett Drugs Ther. 2021 Oct 4; 63(1634):159-60
Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin product to receive this designation in the US. Now a pharmacist can substitute Semglee for Lantus as a lower-cost alternative without permission from the prescriber.
Issue 1616 · January 25, 2021 Free
In Brief: Semglee - A New Insulin Glargine for Diabetes

The FDA has approved Semglee (Mylan), an insulin glargine product similar to Lantus , for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults. Semglee is the second "follow-on"…

Med Lett Drugs Ther. 2021 Jan 25; 63(1616):14-5
The FDA has approved Semglee (Mylan), an insulin glargine product similar to Lantus , for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults. Semglee is the second "follow-on" insulin glargine product to become available in the US; Basaglar , which is also similar to Lantus , was the first. Lantus is a recombinant analog of human insulin that forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours with no pronounced peak effect.
Issue 1571 · May 6, 2019
Insulins for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin…

Med Lett Drugs Ther. 2019 May 6; 61(1571):65-8
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; for most patients, the target A1C is <7%. Metformin is the preferred first-line treatment, but most patients with type 2 diabetes eventually require multidrug therapy and/or insulin to achieve glycemic control.
Issue 1571 · May 6, 2019
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)

View the Expanded Table: Some Available Insulins

Med Lett Drugs Ther. 2019 May 6; 61(1571):e73-7
View the Expanded Table: Some Available Insulins
Issue 1537 · January 1, 2018
Fiasp - Another Insulin Aspart Formulation for Diabetes

The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional…

Med Lett Drugs Ther. 2018 Jan 1; 60(1537):6-7
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog) .
Issue 1529 · September 11, 2017
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes

The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with…

Med Lett Drugs Ther. 2017 Sep 11; 59(1529):147-9
The FDA has approved Xultophy 100/3.6 (Novo Nordisk), a fixed-ratio combination of insulin degludec and the GLP-1 (glucagon-like peptide-1) receptor agonist liraglutide, for once-daily treatment of adults with type 2 diabetes inadequately controlled on basal insulin (<50 units daily) or liraglutide (≤1.8 mg daily).
Issue 1527 · August 14, 2017
Cardiovascular Effects of Some Antidiabetic Drugs

For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic…

Med Lett Drugs Ther. 2017 Aug 14; 59(1527):136-8
For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic retinopathy, nephropathy, neuropathy), but whether it prevents macrovascular complications (myocardial infarction [MI], stroke) has been less clear. The FDA now requires that cardiovascular safety studies be performed for all new drugs for type 2 diabetes.1 Recent findings that some of the newer second-line drugs for type 2 diabetes have cardiovascular benefits have led to new interest in the cardiovascular efficacy and safety of all antidiabetic drugs.
Issue 1512 · January 16, 2017
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to…

Med Lett Drugs Ther. 2017 Jan 16; 59(1512):9-18
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of ≤7%. Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuropathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.
Issue 1511 · January 2, 2017
Another Insulin Glargine (Basaglar) for Diabetes

The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin…

Med Lett Drugs Ther. 2017 Jan 2; 59(1511):3-4
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in 2015.
Issue 1483 · December 7, 2015
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes

The FDA has approved insulin degludec ( Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the…

Med Lett Drugs Ther. 2015 Dec 7; 57(1483):163-4
The FDA has approved insulin degludec ( Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine ( Lantus , Toujeo ) were approved earlier.
Issue 1468 · May 11, 2015
Concentrated Insulin Glargine (Toujeo) for Diabetes

The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the…

Med Lett Drugs Ther. 2015 May 11; 57(1468):69-70
The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the US, and biosimilars are expected to become available.
Issue 139 · March 1, 2014
Drugs for Type 2 Diabetes

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been…

Treat Guidel Med Lett. 2014 Mar; 12(139):17-24
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been shown to prevent the microvascular complications of retinopathy and nephropathy, but whether it prevents macrovascular outcomes remains unclear. Three large trials found that intensive glucose control did not reduce the incidence of macrovascular events. One of these trials (ACCORD) in >10,000 patients with type 2 diabetes, with or at high-risk for cardiovascular disease, found that treating patients intensively with antihyperglycemic drugs to an A1C target of 6.0% for a mean of 3.7 years did not significantly reduce the incidence of major cardiovascular events (the primary endpoint) and was associated with increased all-cause mortality compared to patients treated to an A1C target of 7.0-7.9%. An A1C target of 7-8% may be prudent in older patients and in those with underlying cardiovascular disease, severe hypoglycemia, or multiple diabetes-related complications or co-morbidities.
Issue 1416 · May 13, 2013
Canagliflozin (Invokana) for Type 2 Diabetes

Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.

Med Lett Drugs Ther. 2013 May 13; 55(1416):37-9
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, has been approved by the FDA for oral treatment of type 2 diabetes.
Issue 1395 · July 23, 2012
What Comes After Metformin for Type 2 Diabetes?

Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is…

Med Lett Drugs Ther. 2012 Jul 23; 54(1395):58-9
Most experts agree that lifestyle modifications and metformin ( Glucophage , and others) should be used first to treat patients with type 2 diabetes. If metformin alone fails to control hyperglycemia, there is no general agreement on which drug should be added next. A recent article in The Medical Letter offered some support for a sulfonylurea. Three recent trials published in The Lancet favored the long-acting basal insulin glargine, the glucagon-like peptide (GLP-1) analog exenatide, and the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, respectively. Some of the advantages and disadvantages of these and other available agents are listed in Table 1 on the opposite page.
Issue 1319 · August 24, 2009
Insulin Glargine (Lantus) and Cancer Risk

Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.

Med Lett Drugs Ther. 2009 Aug 24; 51(1319):67-8
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
Issue 71 · July 1, 2008
Drugs for Type 2 Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,…

Treat Guidel Med Lett. 2008 Jul; 6(71):47-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Issue 1238 · July 3, 2006
Insulin Detemir (Levemir), a New Long-Acting Insulin

Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the…

Med Lett Drugs Ther. 2006 Jul 3; 48(1238):54-5
Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus) , the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting insulin.
Issue 1233 · April 24, 2006
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin

Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid…

Med Lett Drugs Ther. 2006 Apr 24; 48(1233):33-4
Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Issue 36 · August 1, 2005
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In…

Treat Guidel Med Lett. 2005 Aug; 3(36):57-62
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In many patients, diet and regular exercise can improve glucose control. Most drugs currently available for management of type 2 diabetes increase insulin supply (sulfonylureas, other secretagogues and insulin itself), decrease insulin resistance (thiazolidinediones) or improve the effectiveness of insulin (biguanides). Alpha-glucosidase inhibitors reduce the rate of glucose absorption. Newer agents such as pramlintide (Symlin) and exenatide (Byetta) have multiple effects to increase satiety and reduce postprandial hyperglycemia.
Issue 1 · September 1, 2002
Drugs for Diabetes

The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most…

Treat Guidel Med Lett. 2002 Sep; 0(1):1-6
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most drugs currently available for management of type 2 diabetes fall into 2 categories: those that increase insulin supply (sulfonylureas, other secretagogues and insulin itself) and those that decrease insulin resistance or improve its effectiveness (biguanides, thiazolidinediones). Alpha-glucosidase inhibitors reduce the rate of glucose absorption.
Issue 1110 · August 6, 2001
Insulin Glargine (Lantus), A New Long-acting Insulin

Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human…

Med Lett Drugs Ther. 2001 Aug 6; 43(1110):65-6
Insulin Glargine (Lantus) is a new long-acting human insulin analog approved by the FDA for treatment of both type 1 and type 2 diabetes. Synthesized by recombinant DNA technology, it differs from human insulin at position 21 in the A-chain where asparagine is replaced by glycine and at the C-terminus of the B-chain where two arginines are added.